Seroatlas · Human Serome Atlas

BLTP2

Bridge-like lipid transfer protein family member 2

Also known as: BCOX, BCOX1, BLTP2_HUMAN, CT101, DKFZp686M0843, FMP27, Hob, KIAA0100, MGC111488

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q14667
Gene: BLTP2
Ensembl: ENSG00000007202
Chromosome: 17
Canonical length: 2235 aa
Protein class: Predicted intracellular proteins
Subcellular location: Nuclear speckles,Cytosol

OverviewNCBI Gene

This gene was initially characterized in human as having high expression levels in breast carcinomas and breast cancer cell lines. This gene also has increased expression in prostrate cancer cells relative to normal prostrate tissues. Expression of this gene is negatively regulated by direct binding of the microRNA miR-195 to its 3' UTR. miR-195 has been shown to modulate the invasiveness of prostrate cancer cells and xenograft metastases by downgrading expression of this gene. In mouse, the protein encoded by this gene was identified as an antigen on acute monocytic leukemia cells. In human, alternative splicing results in multiple transcript variants encoding distinct isoforms; some of these isoforms are predicted to contain an RNA pol II promoter FMP27 protein domain and a Golgi-body-localization APT1 domain. [provided by RefSeq, Apr 2017]

Canonical amino-acid sequenceUniProt

2235 residues, UniProt reviewed canonical sequence.

>Q14667|BLTP2
     1  MPLFFSALLV LLLVALSALF LGRWLVVRLA TKWCQRKLQA ELKIGSFRFF WIQNVSLKFQ
    61  QHQQTVEIDN LWISSKLLSH DLPHYVALCF GEVRIRTDLQ KVSDLSAPFS QSAGVDQKEL
   121  SFSPSLLKIF CQLFSIHVDA INIMVLKVDT SESLWHIQIS RSRFLLDSDG KRLICEVSLC
   181  KINSKVLKSG QLEDTCLVEL SLALDLCLKV GISSRHLTAI TVDVWTLHAE LHEGLFQSQL
   241  LCQGPSLASK PVPCSEVTEN LVEPTLPGLF LLQQLPDQVK VKMENTSVVL SMNSQKRHLT
   301  WTLKLLQFLY HRDEDQLPLR SFTANSDMAQ MSTELLLEDG LLLSQSRQRI VCLNSLKASV
   361  QVTTIDLSAS LVLNTCIIHY RHQEFSHWLH LLALETQGSS SPVLKQRKKR TFPQILAPII
   421  FSTSISNVNI SIQLGDTPPF ALGFNSISLD YQHLRPQSIH QRGVLTVDHL CWRVGSDSHI
   481  QRAPHPPNMH VWGEALVLDS FTLQGSYNQP LGLSSTQSDT LFLDCTIRGL QVEASDTCAQ
   541  CLSRILSLMG PQSGKSAVSR HSSFGESVSL LWKVDLKVED MNLFTLSALV GASEVRLDTL
   601  TILGSAETST VGIQGLVLAL VKSVTEKMQP CCKAPDIPTP VLSLSMLSIT YHSSIRSLEV
   661  QCGAGLTLLW SPPDHMYLYQ HVLATLQCRD LLRATVFPET VPSLALETSG TTSELEGRAP
   721  EPLPPKRLLN LTLEVSTAKL TAFVAEDKFI TLAAESVSLS RHGGSLQAYC PELAAGFDGN
   781  SIFNFKEVEV QLLPELEEMI LHRNPFPALQ TLRNRVWLLS FGSVSVEFPY QYDFSRTLDE
   841  AVGVQKWLKG LHQGTRAWAS PSPVPLPPDL LLKVEHFSWV FLDDVFEVKL HDNYELMKDE
   901  SKESAKRLQL LDAKVAALRK QHGELLPARK IEELYASLER KNIEIYIQRS RRLYGNTPMR
   961  RALLTWSLAG LELVALADAS FHGPEHVVEQ VQELDPGSPF PPEGLDLVIQ WCRMLKCNVK
  1021  SFLVRIRDYP RYLFEIRDWR LMGRLVGTEQ SGQPCSRRRQ ILHLGLPWGN VAVERNMPPL
  1081  KFYHDFHSEI FQYTVVWGPC WDPAWTLIGQ CVDLLTKPSA DPSPPLPWWD KSRLLFHGDW
  1141  HMDIEQANLH QLATEDPYNT TENMHWEWSH LSFHWKPGQF VFKGDLDINV RTASKYDDCC
  1201  FLHLPDLCMT LDLQWLCHGN PHDHHSVTLR APEFLPEVPL GQLHDSYRAF RSENLNLSIK
  1261  MDLTRHSGTI SQPRILLYSS TLRWMQNFWA TWTSVTRPIC RGKLFNNLKP SKKKLGQHYK
  1321  QLSYTALFPQ LQVHYWASFA QQRGIQIECS QGHVFTRGTQ RLIPQAGTVM RRLISDWSVT
  1381  QMVSDLSQVT VHLMASPTEE NADHCLDPLV TKTHLLSLSS LTYQRHSNRT AEEELSARDG
  1441  DPTFHTHQLH LVDLRISWTT TNRDIAFGLY DGYKKAAVLK RNLSTEALKG LKIDPQMPAK
  1501  KPKRGVPTSA SAPPRVNTPS FSGQPDKGSS GGAYMLQKLI EETDRFVVFT EEESGMSDQL
  1561  CGIAACQTDD IYNRNCLIEL VNCQMVLRGA ETEGCVIVSA AKAQLLQCQH HPAWYGDTLK
  1621  QKTSWTCLLD GMQYFATTES SPTEQDGRQL WLEVKNIEEH RQRSLDSVQE LMESGQAVGG
  1681  MVTTTTDWNQ PAEAQQAQQV QRIISRCNCR MYYISYSHDI DPELATQIKP PEVLENQEKE
  1741  DLLKKQEGAV DTFTLIHHEL EISTNPAQYA MILDIVNNLL LHVEPKRKEH SEKKQRVRFQ
  1801  LEISSNPEEQ RSSILHLQEA VRQHVAQIRQ LEKQMYSIMK SLQDDSKNEN LLDLNQKLQL
  1861  QLNQEKANLQ LESEELNILI RCFKDFQLQR ANKMELRKQQ EDVSVVRRTE FYFAQARWRL
  1921  TEEDGQLGIA ELELQRFLYS KVNKSDDTAE HLLELGWFTM NNLLPNAVYK VVLRPQSSCQ
  1981  SGRQLALRLF SKVRPPVGGI SVKEHFEVNV VPLTIQLTHQ FFHRMMGFFF PGRSVEDDEV
  2041  GDEEDKSKLV TTGIPVVKPR QLIATDDAVP LGPGKGVAQG LTRSSGVRRS FRKSPEHPVD
  2101  DIDKMKERAA MNNSFIYIKI PQVPLCVSYK GEKNSVDWGD LNLVLPCLEY HNNTWTWLDF
  2161  AMAVKRDSRK ALVAQVIKEK LRLKSATGSE VRGKLETKSD LNMQQQEEEE KARLLIGLSV
  2221  GDKNPGKKSI FGRRK

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against BLTP2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.35
Highest tissue expression: 49 nTPM

Expression across tissuesHPA

Tissue

parathyroid gland: 49 nTPM
skeletal muscle: 49 nTPM
kidney: 40 nTPM
tongue: 40 nTPM
adipose tissue: 34 nTPM
thyroid gland: 33 nTPM

Single-cell type

syncytiotrophoblasts: 95 nCPM
salivary duct cells: 75 nCPM
neutrophil progenitors: 67 nCPM
megakaryocyte progenitors: 66 nCPM
early primary spermatocytes: 64 nCPM
adrenal medulla cells: 64 nCPM

Immune cell

plasmacytoid DC: 2.9 nTPM
eosinophil: 1.5 nTPM
myeloid DC: 1.3 nTPM
gdT-cell: 1.2 nTPM
MAIT T-cell: 1.2 nTPM
non-classical monocyte: 1.2 nTPM

Brain region

choroid plexus: 92 nTPM
pons: 87 nTPM
thalamus: 82 nTPM
midbrain: 78 nTPM
medulla oblongata: 76 nTPM
hippocampal formation: 76 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.42
gnomAD pLI: 0
DepMap mean gene effect: -0.33
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 6% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Molecular functions

phosphatidylinositol binding

Cellular components

Protein domainsUniProt · Pfam · InterPro

FMP27/BLTP2/Hobbit, GFWDK motif-containing RBG unit
Hobbit
Hobbit/FMP27/BTLP2 family

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of BLTP2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

ACTB

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads BLTP2 as an antibody target. Whether an autoantibody or antibody against BLTP2 could matter depends on whether native BLTP2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

BLTP2 is annotated at the cell surface, where native BLTP2 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label BLTP2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...